Hostname: page-component-7b7567c8c-slfcl Total loading time: 0 Render date: 2026-11-19T14:55:54.609Z Has data issue: false hasContentIssue false

Impact of a remdesivir formulary restriction by antimicrobial stewardship on drug utilization and cost at a safety-net community hospital during the COVID-19 pandemic

Published online by Cambridge University Press:  07 October 2024

Alfredo Jose Mena Lora*
Affiliation:
University of Illinois at Chicago, Chicago, IL, USASaint Anthony Hospital, Chicago, IL, USA
Dylan Huber
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Ella Li
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Romeen Lavani
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Mirza Ali
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Eden Takhsh
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Rodrigo Burgos
Affiliation:
University of Illinois at Chicago, Chicago, IL, USA
*
Corresponding author: Alfredo J. Mena Lora; Email: amenalor@uic.edu.

Abstract

Deploying novel COVID-19 therapies proved challenging amid rapidly evolving data, drug shortages, and conflicting guidelines. We established a remdesivir formulary restriction remdesivir to promote its evidence-based use. This intervention led to changes in remdesivir utilization patterns and cost savings. Formulary restrictions can play an important role in pandemic preparedness and response.

Information

Type
Concise Communication
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Figure 1.RDV formulary restrictions and approval process.

Figure 1

Figure 2.Average monthly DOT/1000 for RDV during our intervention and estimated DOT/1000 without formulary restrictions.

Supplementary material: File

Mena Lora et al. supplementary material

Mena Lora et al. supplementary material
Download Mena Lora et al. supplementary material(File)
File 1.5 MB